Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers.

Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA.

Mol Cancer Res. 2019 Aug;17(8):1652-1664. doi: 10.1158/1541-7786.MCR-19-0144. Epub 2019 May 20.

PMID:
31110156
2.

Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation.

Zagorski JW, Turley AE, Freeborn RA, VanDenBerg KR, Dover HE, Kardell BR, Liby KT, Rockwell CE.

Biochem Pharmacol. 2018 Jan;147:67-76. doi: 10.1016/j.bcp.2017.11.005. Epub 2017 Nov 15.

3.

Inhibition of early T cell cytokine production by arsenic trioxide occurs independently of Nrf2.

VanDenBerg KR, Freeborn RA, Liu S, Kennedy RC, Zagorski JW, Rockwell CE.

PLoS One. 2017 Oct 19;12(10):e0185579. doi: 10.1371/journal.pone.0185579. eCollection 2017.

4.

Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.

Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS.

Clin Cancer Res. 2017 Feb 15;23(4):985-991. doi: 10.1158/1078-0432.CCR-16-1454. Epub 2016 Oct 7.

5.

The Nrf2 activator, tBHQ, differentially affects early events following stimulation of Jurkat cells.

Zagorski JW, Turley AE, Dover HE, VanDenBerg KR, Compton JR, Rockwell CE.

Toxicol Sci. 2013 Nov;136(1):63-71. doi: 10.1093/toxsci/kft172. Epub 2013 Aug 14.

Supplemental Content

Loading ...
Support Center